Company news

COSCIENS Biopharma Inc. news in 2015

COSCIENS Biopharma Inc.'s news releases, calls and decks from 2015, newest first.

View company

Aeterna Zentaris Affirms Fundamental Strength of Business

November 25, 2015

Aeterna Zentaris Confirms No Corporate Developments

November 24, 2015

Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement

November 24, 2015

Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD

November 19, 2015

Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance

November 18, 2015

Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

November 16, 2015

Aeterna Zentaris Announces Exercise of Series B Warrants

November 12, 2015

Aeterna Zentaris Urges Shareholders to Vote in Favor of the Share Consolidation and Highlights Support from ISS and Glass Lewis

November 11, 2015

Aeterna Zentaris Reports Third Quarter Financial and Operating Results

November 5, 2015

Aeterna Zentaris Announces Agreement to Exercise Substantially All Remaining Series B Warrants

November 2, 2015

Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation

October 27, 2015

Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results on November 6, 2015

October 23, 2015

Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular

October 16, 2015

Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer

October 13, 2015

Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office

October 12, 2015

Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer

September 28, 2015

Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment

September 25, 2015

Aeterna Zentaris Announces Dismissal of Class Action Lawsuit

September 24, 2015

Aeterna Zentaris Announces Amendment to Series B Warrants

September 21, 2015

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York

September 3, 2015

Aeterna Zentaris Reports Second Quarter Financial and Operating Results

August 13, 2015

Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

August 11, 2015

Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015

August 6, 2015

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston

August 4, 2015

Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

July 29, 2015

Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology

July 28, 2015

Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® [Somatropin (rDNA origin) for Injection]

July 27, 2015

Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen(TM) in AGHD Meets EMA's Study-Design Expectations

May 26, 2015

Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting

May 11, 2015

Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results

May 7, 2015

Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.

May 7, 2015

Aeterna Zentaris to Announce First Quarter 2015 Financial and Operating Results on May 7, 2015 and Hold Annual & Special Shareholders Meeting on May 8, 2015

May 1, 2015

Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer

April 27, 2015

Aeterna Zentaris to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference in Toronto

April 23, 2015

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc.

April 23, 2015

Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin

April 16, 2015

Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen(TM) in AGHD Following Successful Meeting with FDA

April 13, 2015

Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina

March 31, 2015

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results

March 17, 2015

Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants

March 11, 2015

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015

March 10, 2015

Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants

March 6, 2015

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

March 5, 2015

Aeterna Zentaris to Present at Roth Conference 2015

March 2, 2015

Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco

January 6, 2015